Navigation Links
Estrogen Supplements May Raise Odds of Benign Breast Disease
Date:4/8/2008

Women on the hormone more than doubled the risk for this precancerous condition

TUESDAY, April 8 (HealthDay News) -- Women who took a common form of estrogen as hormone replacement therapy during menopause more than doubled their risk for certain types of benign breast disease compared with women who took a placebo, researchers say.

One such condition -- benign proliferative breast disease -- is relatively common and has been linked with an increased risk of breast cancer.

The clinical implication for women contemplating the use of supplemental estrogen "doesn't really change," said study author Dr. Tom Rohan, chairman of the department of epidemiology and population health at the Albert Einstein College of Medicine in New York City.

"It's the idea that women need to balance the benefits and risks," he said. This new finding does point to an added risk, however, Rohan added.

His team published the study online April 8 in the Journal of the National Cancer Institute.

Until now, there have been no randomized studies on the effect of conjugated equine estrogen (CEE), a type of hormone replacement therapy (HRT), on the risk of developing benign proliferative breast disease. Randomized trials are considered the gold standard of science.

The current data comes from the Women's Health Initiative CEE trial, in which almost 11,000 postmenopausal women were randomly assigned to receive CEE or a placebo.

Women taking CEE had more than double the risk of developing benign proliferative breast disease over an average follow-up of almost seven years, the team found.

It is thought that invasive breast cancer can result from a succession of conditions, with benign proliferative breast disease without atypia (cell abnormalities) sometimes being followed by proliferative disease with atypia before the development of in situ (localized) cancer.

This study did not see an actual increase in the risk of developing invasive breast cancer but the progression from benign proliferative breast disease to invasive breast cancer could take a decade, in which case this study was not long enough to note that change.

The progress of the women in the trial is still being followed, the researchers noted.

The Womens Health Initiative has also found that women taking estrogen plus another hormone, progestin, had an increased risk both of breast cancer and of benign proliferative breast disease after only about five years of follow-up. This may suggest that progestin plays a role in breast cancer development, the authors stated.

"This makes perfect sense," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "Estrogen does stimulate breast tissue activity and my concern is that, if you do move along a continuum as the hypothesis states, as you stimulate the breast are you going to be able to predict which women are going to develop into something worse and women who are going to stay in a benign state. I can't predict which of those women will develop [breast cancer] down the line but we know that this agent is highly stimulatory to breast tissue so the question is, do you want to be taking an agent that stimulates breast tissue?"

More information

The U.S. National Heart, Lung, and Blood Institute has more on the Women's Health Initiative.



SOURCES: Tom Rohan, M.D., Ph.D., chairman, department of epidemiology and population health, Albert Einstein College of Medicine, New York City; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; April 8, 2008, Journal of the National Cancer Institute online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New link between estrogen and breast cancer
2. UCLA study identifies designer estrogen as potential MS drug
3. Cholesterol byproduct blocks heart health benefits of estrogen
4. Gene May Influence Breast Cancer-Estrogen Link
5. Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
6. Estrogen Levels in Blood Predict Breast Cancers Return
7. Mitochondria play role in pathogenesis of AD and estrogen-induced neuroprotection
8. New study finds adverse effects of estrogen replacement therapy are related to the dose
9. Antioxidant Supplements May Raise Womens Skin Cancer Risk
10. Vitamin D Supplements May Lengthen Life
11. Wellcorps International Unveils New Nutritional Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Estrogen Supplements May Raise Odds of Benign Breast Disease
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing list ... seven other locations throughout the Southeast, from Orlando to Huntsville and in between. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... award winner and inspirational speaker Jan Fox will serve as keynote speaker at ... will provide participants with tools to more effectively communicate with their own organizational ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... been awarded the prestigious Distinguished Emerald Club of the World award, as determined ... magazine, one of the most respected trade publications serving private clubs. , “We’d ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week ... series of monitor mounts ever. , “Our goal was to develop a product ... install system that we have ever created.” said Darren Hulsey, Product Manager for Workrite ...
(Date:2/10/2016)... ... 2016 , ... A new leadership team for Mid-South Youth Camp, operated by ... the announcement Monday night, Feb. 8, prior to the evening session of the university’s ... creator of GO! Camp, has been named director. Gayle McDonald, currently the assistant director ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 Urologix, the market leader for in-office ... Prostatic Hyperplasia (BPH), announces new private ownership and is ... medical device industry veteran of more than 20 years, ... Plymouth, Minn. The ... and Prostiva® RF Therapy, will continue to be broadly ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: ... 1-for-100 reverse split of its issued and outstanding shares ... on Thursday, February 11, 2016. The Company,s common stock ... number 76303T308 and temporary ticker symbol "RCHAD". After 20 ... the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: